New investigations into retatrutide, a dual activator for GLP-1 and GIP receptors, are showing promising results in treating excess mass and related non-insulin-dependent disease. Initial data suggest a distinct action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/